US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.26 against a street estimate of 0.96 — a beat of 31.3%.
Analysts rate Bausch Health Companies Inc a hold (1 buy, 5 hold, 1 sell out of 7) with an average price target of $7.50.
| Fund | Stake |
|---|---|
| Paulson & Company Inc | 19.59% |
| Goldentree Asset Management LP | 9.27% |
| Royal Bank of Canada | 3.04% |
| Nomura Holdings Inc | 2.40% |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 2.14% |
| Vanguard Capital Management, LLC | 1.98% |
| MFN Partners Management, LP | 1.60% |
| Kohlberg Kravis Roberts & Co LP | 1.40% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-29 |
| Board / officer change · Q2 2026 | 2026-07-01 |
| Shareholder vote results · Q2 2026 | 2026-05-19 |
| Quarterly report · Q1 2026 | 2026-04-30 |
| Results announced · Q2 2026 | 2026-04-29 |
| Proxy statement · Q2 2026 | 2026-04-08 |
| Annual report FY2025 | 2026-02-19 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bausch Health Companies Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.